The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Abuchowski, A., van Es, T., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes
Cerutti, A., Cols, M., & Puga, I. (2013) · Nature Reviews Immunology · doi:10.1038/nri3383 · Cited by 777
Large unilamellar liposomes with low uptake into the reticuloendothelial system
Allen, T. M., & Chonn, A. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80506-9 · Cited by 729
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens
Helmy, K. Y., Katschke, K. J., Gorgani, N. N., Kljavin, N. M., Elliott, J. M., Diehl, L., Scales, S. J., Ghilardi, N., & van Lookeren Campagne, M. (2006) · Cell · doi:10.1016/j.cell.2005.12.039 · Cited by 628
Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W.-J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z.-X., Modi, M. W., et al. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000082g · Cited by 611
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Szebeni, J. (2005) · Toxicology · doi:10.1016/j.tox.2005.07.023 · Cited by 611
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G., & Richette, P. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.720969 · Cited by 587
L‐asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase
Pieters, R., Hunger, S. P., Boos, J., Rizzari, C., Silverman, L., Baruchel, A., Goekbuget, N., Schrappe, M., & Pui, C. (2011) · Cancer · doi:10.1002/cncr.25489 · Cited by 569
Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.005 · Cited by 557
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
Schellekens, H. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80075-3 · Cited by 556
Self-citationDelivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Chen, C.-J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28075 · Cited by 476
Introduction to current and future protein therapeutics: A protein engineering perspective
Carter, P. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.013 · Cited by 467
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Wang, X., Ishida, T., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.010 · Cited by 421
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner
Ishida, T., Wang, X., Shimizu, T., Nawata, K., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.015 · Cited by 382
Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1861 · Cited by 350
Questioning the use of PEGylation for drug delivery
Verhoef, J. J. F., & Anchordoquy, T. J. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0176-5 · Cited by 342
Self-citationThe Immunogenicity of Polyethylene Glycol: Facts and Fiction
Schellekens, H., Hennink, W. E., & Brinks, V. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1067-7 · Cited by 340
Self-citationIshida, T., Atobe, K., Wang, X., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.017 · Cited by 287
Richter, A. W., & Åkerblom, E. (1983) · International Archives of Allergy and Immunology · doi:10.1159/000233309 · Cited by 282
Lipsky, P. E., Calabrese, L. H., Kavanaugh, A., Sundy, J. S., Wright, D., Wolfson, M., & Becker, M. A. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4497 · Cited by 266
Hamad, I., Hunter, A. C., Szebeni, J., & Moghimi, S. M. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.08.276 · Cited by 253
PEGylated Protein Drugs: Basic Science and Clinical Applications
(2009) · doi:10.1007/978-3-7643-8679-5 · Cited by 241
Richter, A. W., & Åkerblom, E. (1984) · International Archives of Allergy and Immunology · doi:10.1159/000233512 · Cited by 229
Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling
Gauld, S. B., Benschop, R. J., Merrell, K. T., & Cambier, J. C. (2005) · Nature Immunology · doi:10.1038/ni1256 · Cited by 219
Szebeni, J., Bedőcs, P., Rozsnyay, Z., Weiszhár, Z., Urbanics, R., Rosivall, L., Cohen, R., Garbuzenko, O., Báthori, G., Tóth, M., et al. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.06.003 · Cited by 219
Accelerated Blood Clearance Phenomenon Upon Repeated Injection of PEG-modified PLA-nanoparticles
Ishihara, T., Takeda, M., Sakamoto, H., Kimoto, A., Kobayashi, C., Takasaki, N., Yuki, K., Tanaka, K.-I., Takenaga, M., Igarashi, R., et al. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9943-x · Cited by 195
Role of the methoxy group in immune responses to mPEG-protein conjugates
Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Saifer, M. G. P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200551b · Cited by 185
Innate B cell helpers reveal novel types of antibody responses
Vinuesa, C. G., & Chang, P.-P. (2013) · Nature Immunology · doi:10.1038/ni.2511 · Cited by 182
Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats
Ichihara, M., Shimizu, T., Imoto, A., Hashiguchi, Y., Uehara, Y., Ishida, T., & Kiwada, H. (2010) · Pharmaceutics · doi:10.3390/pharmaceutics3010001 · Cited by 168
Moghimi, S. M., Andersen, A. J., Hashemi, S. H., Lettiero, B., Ahmadvand, D., Hunter, A. C., Andresen, T. L., Hamad, I., & Szebeni, J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.003 · Cited by 167
Interferon: Cellular Executioner or White Knight?
Maher, S., Romero-Weaver, A., Scarzello, A., & Gamero, A. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780597907 · Cited by 163
Koide, H., Asai, T., Hatanaka, K., Akai, S., Ishii, T., Kenjo, E., Ishida, T., Kiwada, H., Tsukada, H., & Oku, N. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.022 · Cited by 157
B cell recognition of membrane-bound antigen: an exquisite way of sensing ligands
Carrasco, Y. R., & Batista, F. D. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.03.013 · Cited by 155
Accelerated Clearance of Polyethylene Glycol-Modified Proteins by Anti-Polyethylene Glycol IgM
Cheng, T., Wu, P.-Y., Wu, M., Chern, J., & Roffler, S. R. (1999) · Bioconjugate Chemistry · doi:10.1021/bc980143z · Cited by 147
Ishida, T., Kashima, S., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.11.009 · Cited by 125
Eggebeen, A. T. (2007) · PubMed · Cited by 123
A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
Hu, X. S., Miller, L., Richman, S., Hitchman, S., Glick, G., Liu, S., Zhu, Y., Crossman, M., Nestorov, I. A., Gronke, R. S., et al. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011407068 · Cited by 119
Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis
Macdougall, I. C., Provenzano, R., Sharma, A. K., Spinowitz, B., Schmidt, R. J., Pérgola, P. E., Zabaneh, R. I., Tong-Starksen, S., Mayo, M. R., Tang, H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1203166 · Cited by 118
Saifer, M. G. P., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Sherman, M. R. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.07.014 · Cited by 112
Peginesatide in Patients with Anemia Undergoing Hemodialysis
Fishbane, S. N., Schiller, B. M., Locatelli, F., Covic, A. C., Provenzano, R., Więcek, A., Levin, N. W., Kaplan, M., Macdougall, I. C., Francisco, C. A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1203165 · Cited by 111
Modifications of therapeutic proteins: challenges and prospects
Jenkins, N. (2007) · Cytotechnology · doi:10.1007/s10616-007-9075-2 · Cited by 109
Shimizu, T., Ichihara, M., Yoshioka, Y., Ishida, T., Nakagawa, S., & Kiwada, H. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00276 · Cited by 106
Szebeni, J., Bedöcs, P., Urbanics, R., Bünger, R., Rosivall, L., Tóth, M., & Barenholz, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.029 · Cited by 102
Bomalaski, J. S., Holtsberg, F. W., Ensor, M., & Clark, M. A. (2002) · PubMed · Cited by 98
Shimizu, T., Ishida, T., & Kiwada, H. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.08.274 · Cited by 94
Armstrong, J. K. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8679-5_9 · Cited by 81
Anti-polyethyleneglycol Antibody Response to PEGylated Substances
Ishida, T., & Kiwada, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00107 · Cited by 78
Complement activation associated with polysorbate 80 in beagle dogs
Qiu, S., Liu, Z., Hou, L., Li, Y., Wang, J., Wang, H., Du, W., Wang, W., Qin, Y., & Liu, Z. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.10.021 · Cited by 67
Liu, Y., Reidler, H., Pan, J., Milunic, D., Qin, D., Chen, D., Vallejo, R. P., & Yin, R. (2011) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2011.07.003 · Cited by 64
Immunogenicity of Polyethylene Glycol (PEG)
Garay, R. P. (2011) · The Open Conference Proceedings Journal · doi:10.2174/2210289201102010104 · Cited by 60
Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs
Garratty, G. (2004) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2004.06.005 · Cited by 54
Li, C., Zhao, X., Wang, Y., Yang, H., Li, H., Li, H., Tian, W., Yang, J., & Cui, J. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.012 · Cited by 48
Safety, Tolerability, and Immunogenicity of Interferons
Tovey, M. G., & Lallemand, C. (2010) · Pharmaceuticals · doi:10.3390/ph3041162 · Cited by 42
Nagao, A., Lila, A. S. A., Ishida, T., & Kiwada, H. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.11.015 · Cited by 39
Tillmann, H. L., Ganson, N. J., Patel, K., Thompson, A. J., Abdelmalek, M. F., Moody, T., McHutchison, J. G., & Hershfield, M. S. (2010) · Journal of Hepatology · doi:10.1016/s0168-8278(10)60309-1 · Cited by 37
Chapanian, R., Constantinescu, I., Rossi, N. A. A., Medvedev, N., Brooks, D. E., Scott, M. D., & Kizhakkedathu, J. N. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.015 · Cited by 35
The safety and efficacy of peginesatide in patients with CKD
Eckardt, K. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.42 · Cited by 20
Mikhail, A. I. (2012) · Journal of Blood Medicine · doi:10.2147/jbm.s23270 · Cited by 15
Scagnolari, C., Trombetti, S., Soldà, A. M., Milella, M. S., Gaeta, G. B., Angarano, G., Scotto, G., Caporaso, N., Morisco, F., Cozzolongo, R., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03729.x · Cited by 14
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
Metadata
- Authors
- Verhoef, J. J. F., Carpenter, J. F., Anchordoquy, T. J., & Schellekens, H.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 19
- Issue
- 12
- Pages
- 1945-1952
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2056609366
- Cited by
- 267
- References
- 69
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.